Two oral chelattor consumption in patients with beta thalassemia.
Conditions
Interventions
Intervention 1: Patients in intervention group will receive Deferasirox + Deferiprone. Deferiprone will be consumed with a previous dosage and deferasirox will be administered in a standard dosage ran
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: ß thalassemia patients who have continuous blood transfusions receiving deferoxamine with deferiprone.
Exclusion criteria
Exclusion criteria: Patients who changes their chelator during the study. Patients who changes thier blood transfusion pattern during the study Patients with liver complications (rise of aminotransferase >5 times of baseline) Pregnant women Patients with renal insufficiency with a creatinine clearance (GFR) of less than 30 ml / min. patients with renal adverese effect of chelating agent (rise serum creatinine>2 time of baseline orproteinuria)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ferritine level. Timepoint: baseline and after 6 months. Method of measurement: blood sample.;Quality of life. Timepoint: baseline and after 6 months. Method of measurement: Questionare.;MRI indinces. Timepoint: baseline and after 6 months. Method of measurement: MRI. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaba Ghaffary
Tabriz University of Medical Sciences
Outcome results
None listed